Characterization of buffy coat-derived granulocytes for clinical use: a comparison with granulocyte colony-stimulating factor/dexamethasone-pretreated donor-derived products.

Autor:	van de Geer A; Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands., Gazendam RP; Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands., Tool AT; Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands., van Hamme JL; Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands., de Korte D; Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands.; Department of Product and Process Development, Sanquin Blood Bank, Amsterdam, The Netherlands., van den Berg TK; Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands., Zeerleder SS; Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands.; Department of Hematology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Kuijpers TW; Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands.; Department of Pediatric Hematology, Immunology & Infectious disease, Emma Children's Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Jazyk:	angličtina
Zdroj:	Vox sanguinis [Vox Sang] 2017 Feb; Vol. 112 (2), pp. 173-182. Date of Electronic Publication: 2017 Jan 25.
DOI:	10.1111/vox.12481
Abstrakt:	Background and Objectives: Buffy coat-derived granulocytes have been described as an alternative to the apheresis product from donors pretreated with dexamethasone and granulocyte colony-stimulating factor (G-CSF). The latter is - dependent on the local and national settings - obtained following a demanding and time-consuming procedure, which is undesirable in critically ill septic patients. In contrast, buffy coat-derived products have a large volume and are often heavily contaminated with red cells and platelets. We developed a new pooled buffy coat-derived product with high purity and small volume, and performed a comprehensive functional characterization of these granulocytes. Materials and Methods: We pooled ten buffy coats following the production of platelet concentrates. Saline 0·9% was added to decrease the viscosity and the product was split into plasma, red cells and a 'super' buffy coat. Functional data of the granulocytes were compared to those obtained with granulocytes from healthy controls and G-CSF/dexamethasone-pretreated donors. Results: Buffy coat-derived granulocytes showed adhesion, chemotaxis, reactive oxygen species production, degranulation, NETosis and in vitro killing of Staphylococcus aureus, Escherichia coli and Aspergillus species comparable to control and G-CSF/dexamethasone-derived granulocytes. Candida killing was superior compared to G-CSF/dexamethasone-derived granulocytes. Immunophenotyping was normal; especially no signs of activation in the buffy coat-derived granulocytes were seen. Viability was reduced. Buffy coats are readily available in the regular blood production process and would take away the concerns around the apheresis product. Conclusion: The product described appears a promising alternative for transfusion purposes. (© 2017 International Society of Blood Transfusion.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF